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 LIST OF ABBREVIATIONS 
 
API : Active Pharmaceutical Ingredient 
°C : Degree centigrade 
CSP : Chiral Stationary Phase 
FDS : Forced Degradation Studies 
Fig. : Figure 
ELSD : Evaporative Light Scattering Detector 
GHP : G Hydrophilic Polypropylene 
HETP : Height Equivalent to a Theoretical Plate 
HPLC : High Performance Liquid Chromatography 
HPTLC : High Performance Thin Layer Chromatography 
IS : Internal Standard 
LC : Liquid Chromatography 
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NMR : Nuclear Magnetic Resonance 
NMT : Not  More Than 
NP : Normal Phase 
ODS : Octa Decyl Silane 
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PMR : Proton Magnetic Resonance 
PVDF : Polyvinylidene difluoride 
RI : Refractive Index 
RSD : Relative Standard Deviation 
RS : Reference Standard 
SD : Standard Deviation 
TF : Tailing Factor 
USP : United States Pharmacopoeia 
VWD : Variable Wavelength Detector 
WRS : Working Reference Standard 
µg /ml : Microgram per milli liter 
µg : Microgram 
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1.0 INTRODUCTION 
1.1 High-Performance Liquid Chromatography (HPLC) 
High-performance liquid chromatography, is a chromatographic technique used to 
separate the components in a mixture, to identify each component, and to quantify 
each component. The method involves a liquid sample being passed over a solid 
adsorbent material packed into a column using a flow of liquid solvent. Each analyte 
in the sample interacts slightly differently with the adsorbent material, thus retarding 
the flow of the analytes. If the interaction is weak, the analytes flow off the column in 
a short amount of time, and if the interaction is strong, then the elution time is long.  
(Sharma B.K, 1994).  
Chromatography may be defined as a method of separating a mixture of 
components into individual components through equilibrium distribution between two 
phases. (Chatwal G.R, 1998) 
The HPLC method was considered the choice of estimation, since this method 
is the most powerful of all chromatographic and other separative methods. The HPLC 
method has enabled analytical chemist to attain great success in solving his analytical 
problems. The HPLC is the method of choice in the field of analytical chemistry, 
since this method is specific, robust, linear, precise, and accurate and the limit of 
detection is low and also it offers the following advantages. (Beckett, 2002) 
The schematic representation of an HPLC instrument typically includes a 
sampler, pumps, and a detector. The sampler brings the sample mixture into the 
mobile phase stream which carries it into the column. The pumps deliver the desired 
flow and composition of the mobile phase through the column. The detector generates 
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a signal proportional to the amount of sample component emerging from the column, 
hence  allowing  for  quantitative  analysis  of  the  sample  components.  A  digital  
microprocessor and user software control the HPLC instrument and provide data 
analysis. Some models of mechanical pumps in a HPLC instrument can mix multiple 
solvents together in ratios changing in time, generating a composition gradient in the 
mobile phase. Various detectors are in common use, such as UV/Vis, photodiode 
array (PDA) or Refractive Index (RI). 
 
SCHEMATIC REPRESENTATION OF HPLC SYSTEM 
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1.2 Components Of HPLC System 
1.2.1 Pump 
Pump  generates  a  flow  of  eluent  from  the  solvent  reservoir  to  the  system.   Most  
pumps used in current LC systems generate the flow by back-and-forth motion of a 
motor-driven piston (reciprocating pumps). Because of this piston motion, it produces 
“pulses”. There have been large system improvements to reduce this pulsation and the 
recent pumps create much less pulse compared to the older ones. Recent analysis 
requires very high sensitivity to quantify a small amount of analytes, and thus even a 
minor change in the flow rate can influence the analysis. Therefore, the pumps 
required for the high sensitivity analysis needs to be highly precise. 
1.2.2 Injector 
An injector is placed next to the pump. The simplest method is to use a syringe, and 
the sample is introduced to the flow of eluent. Since the precision of LC measurement 
is largely affected by the reproducibility of sample injection, the design of injector is 
an important factor. The most widely used injection method is based on sampling 
loops. The use of autosampler (auto-injector) system is also widely used that allows 
repeated injections in a set scheduled-timing. 
1.2.3 Column 
The separation is performed inside the column; therefore, it can be said that the 
column is the heart of an LC system. The packing material generally used is silica or 
polymer gels. The eluent used for LC varies from acidic to basic solvents. Most 
column housing is made of stainless steel, since stainless is tolerant towards a large 
variety of solvents. However, for the analysis of some analytes such as biomolecules 
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and ionic compounds, contact with metal is not desired, thus polyether ether ketone 
(PEEK) column housing is used instead. 
Table 1 - COLUMN SELECTION FLOW CHART 
Sample  LC mode Column choice 
  
 Reverse Phase-ion pair 
(allows neutral and charged 
compounds to be 
simultaneously analyzed) 
C18, C8, C6, C4, C2, TMS, 
CN, amino (not for 
carbonyl compounds), 
phenyl, Hamilton PRP-1 
(pH 1-13) 
Basic or 
Acidic 
   
  
   Ion suppression 
 
 
C18, C8, C6, C4, C2, TMS, 
CN, amino (not for 
carbonyl compounds), 
phenyl, Hamilton PRP-1 
(pH 1-13) 
Ionizable  Ion Exchange  
  
 
Anionic  Strong Anion exchange 
  
 
Cationic 
Strong Cation exchange 
 
      Normal phase Increasing polarity of 
bonded phases diol 
   CN 
Neutral    NH2  
   Silica  
  Reverse phase Alumina 
    Increasing polarity of 
bonding phase 
   C18   
   C8 
   Phenyl 
   C2 
   TMS 
   CN 
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1.2.4 Detector 
Separation of analytes is performed inside the column, whereas a detector is used to 
observe the obtained separation. The composition of the eluent is consistent when no 
analyte is present. While the presence of analyte changes the composition of the 
eluent. What detector does is to measure these differences. This difference is 
monitored as a form of electronic signal.  (Snyder L.R, Kirkland J.J 1983) 
1.2.5 On-line detectors: 
· Refractive index 
· UV/Vis Fixed wavelength 
· UV/Vis Variable wavelength 
· UV/Vis Diode array 
· Fluorescence 
· Conductivity 
· Mass-spectrometric (LC/MS) 
· Evaporative light scattering 
1.2.6 Off-line detector: 
· FTIR spiral disk monitor; requires sample transfer on the germanium disk and 
the following scanning in FTIR instrument.  
1.2.7 Recorder 
The change in eluent detected by a detector is in the form of electronic signal, and 
thus it is still not visible to our eyes. Nowadays, computer based data processor 
(integrator) is more common. There are software that are specifically designed for LC 
system. It provides not only data acquisition, but features like peak-fitting, base line 
correction, automatic concentration calculation, molecular weight determination, etc. 
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1.2.8 Degasser 
The eluent used for LC analysis may contain gases such as oxygen that are non-
visible to our eyes. When gas is present in the eluent, this is detected as a noise and 
causes unstable baseline. Generally used method includes sparging (bubbling of inert 
gas),  use  of  aspirator,  distillation  system,  and/or  heating  and  stirring.  However,  the  
method is  not  convenient  and  also  when the  solvent  is  left  for  a  certain  time period  
(e.g., during the long analysis), gas will dissolve back gradually. Degasser uses 
special polymer membrane tubing to remove gases. The numerous very small pores 
on the surface of the polymer tube allow the air  to go through while preventing any 
liquid to go through the pore. By placing this tubing under low pressure container, it 
created pressure differences inside and outside the tubing (higher inside the tubing). 
This difference let the dissolved gas to move through the pores and remove the gas. 
Compared to classical batch type degassing, the degasser can be used on-line, it is 
more convenient and efficient.  
1.2.9 Column Heater 
The LC separation is often largely influenced by the column temperature. Also for 
some analysis,  such  as  sugar  and  organic  acid,  better  resolutions  can  be  obtained  at  
elevated temperature (50~80°C). It is also important to keep stable temperature to 
obtain repeatable results even it is analyzed at around room temperature. There are 
possibilities that small different of temperature causes different separation results.  
Thus columns are generally kept inside the column oven (column heater). 
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1.3 Introduction To HPLC Method Development 
Method development has following steps:  (Willard H.H, Merritt L.L, Dean J.A. 
and settle F.A,7th Edn) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A good method development strategy should require only as many experimental runs 
as  are  necessary  to  achieve  the  desired  final  result.  Finally  method  development  
should be as simple as possible, and it should allow the use of sophisticated tools such 
as computer modelling. (Synder K.L, Krikland J.J and Glajch J.L, 1983). 
Collect information on sample, define separation goals 
Need for special HPLC procedure, sample pretreatment, etc. 
Choose detector and detector settings 
Choose LC method, preliminary run, select best separation conditions 
Optimize separation conditions 
Check for problems 
 
  Quantitative calibration 
Recover purified material Qualitative method 
Validate method for release to routine laboratory 
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1.4 Important factors to obtain reliable method 
The important factors, which are to be taken into account to obtain reliable 
quantitative analysis, are: 
1. Careful sampling and sample preparation.  
2. Appropriate choice of the column. 
3. Choice  of  the  operating  conditions  to  obtain  the  adequate  resolution  of  the  
mixture. 
4. Reliable performance of the recording and data handling systems. 
5. Suitable integration/peak height measurement technique. 
6. The mode of calculation best suited for the purpose 
7. Validation of the developed method. 
1.4.1 Careful Sampling And Sample Preparation 
Before beginning method development, it is need to review what is known about the 
sample in order to define the goals of separation. The sample related information that 
is important is summarized in following Table 2 
Table: 2 
Number of compounds present 
Chemical structures 
Molecular weights of compounds 
pKa values of compounds 
UV spectra of compounds 
Concentration range of compounds in samples of interest 
Sample solubility 
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The  chemical  composition  of  the  sample  can  provide  valuable  clues  for  the  best  
choice of initial conditions for an HPLC separation.  
1.4.2  Separation Goals  (Snyder et al., 1997, Sharma B.K., 1980) 
The goals of HPLC separation need to be specified clearly, which include: 
· The use of HPLC to isolate purified sample components for spectral 
identification or quantitative analysis. 
· It may be necessary to separate all degradants or impurities from a product for 
reliable content assay. 
· In quantitative analysis, the required levels of accuracy and precision should be 
known (a precision of ± 1 to 2% is usually achievable). 
· Whether a single HPLC procedure is sufficient for raw material or one or more 
different procedures are desired for formulations. 
· When the number of samples for analysis at one time is greater than 10, a run 
time of less than 20 minutes often will be important.  
1.4.3 Sample preparation 
Samples come in various forms:            
· Solutions ready for injection 
· Solutions that require dilution, buffering, addition of an internal standard or 
other volumetric manipulation 
· Solids must be dissolved or extracted 
· Samples that require pretreatment to remove interferences and/or protect the 
column or equipment from damage. 
Most samples for HPLC analysis require weighing and /or volumetric dilution before 
injection. Best results are often obtained when the composition of the sample solvent 
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is close to that of the mobile phase since this minimizes baseline upset and other 
problems. Some samples require a partial separation (pretreatment) prior to HPLC, 
because of need to remove interferences, concentrate sample analytes or eliminate 
“column killers”.  
The samples may be of two types, regular or special. The regular samples are typical 
mixtures of small molecules (<2000Da) that can be separated by normal starting 
conditions. Whereas special samples are better separated under customized conditions 
given in Table: 3                     
Table 3 
Sample Requirements 
Inorganic ions Detection is primary problem; use ion chromatography. 
Isomers Some isomers can be separated by reversed-phase HPLC 
and are then classified as regular samples; better separations 
of isomers are obtained using either (1) normal-phase HPLC 
or (2) reversed-phase separations with cyclodextrin-silica 
columns. 
Enantiomers These compounds require “chiral” conditions for their 
separation. 
Biological Several factors make samples of this kind “special”: 
molecular conformation, polar functionality, and a wide 
range of hydrophobicity. 
Macromolecules “Big” molecules require column packings with large pores 
(>>10-nm diameters); in addition, biological molecules 
require special conditions as noted above. 
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1.4.4 Choice of the Column 
 The selection of the column in HPLC is somewhat similar to the selection of 
columns in G.C, in the sense that, in the adsorption and partition modes, the 
separation mechanism is based on inductive forces, dipole-dipole interactions and 
hydrogen bond formation. In case of ion-exchange chromatography, the separation is 
based on the differences in the charge, size of the ions generated by the sample 
molecules  and  the  nature  of  ionisable  group  on  the  stationary  phase.  In  the  case  of  
size-exclusion chromatography the selection of the column is based on the molecular 
weight and size of the sample components. Selection of columns based on the method 
is briefly summarized in Table 4. 
    Table: 4 
Method/ Description/Columns Preferred Method 
Reversed-phase HPLC  
Uses water- organic mobile phase  
Columns: C18 (ODS),  C8, phenyl, 
trimethylsilyl (TMS), cyano. 
First choice for most samples, especially 
neutral or non-ionized compounds that 
dissolve in water-organic mixtures 
Ion-pair HPLC  
Uses water-organic mobile phase,  
a buffer to control pH, and an  
Ion-pair reagent  
Columns: C18, C8, Cyano 
Acceptable choice for   ionic or ionisable 
compounds, especially bases or cations. 
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Method/ Description/Columns Preferred Method 
Normal-phase HPLC  
Uses mixtures of organic solvents as 
mobile phase Columns: cyano, diol, 
amino, silica 
   Good second choice when reversed-
phase or ion-pair HPLC is ineffective; 
first choice for lipophilic samples that do 
not dissolve well in water-organic 
mixtures; first choice for mixtures of 
isomers and for preparative HPLC 
 
1.4.5 Operating conditions to obtain the adequate resolution of the mixture 
Most of the drugs come under the category of regular samples. Regular samples mean 
typical mixtures of small molecules (<2000Da) that can be separated using more or 
less standardized starting conditions. Regular samples can be further classified as 
neutral or ionic. Samples classified as ionic include acids, bases, amphoteric 
compounds  and     organic  salts.  If  the  sample  is  neutral,  buffers  or  additives  are  
generally not required in the mobile phase.  
Acids or bases usually require the addition of a buffer to the mobile phase. For basic 
or cationic samples, less acidic reverse phase columns are recommended. Based on 
recommendations of the conditions, the first exploratory run is carried and then 
improved systematically. On the basis of the initial exploratory run isocratic or 
gradient elution can be selected as most suitable. If typical reverse-phase conditions 
provided inadequate sample retention, it suggests the use of either ion-pair or normal 
phase HPLC. Alternatively, the sample may be strongly retained with 100% ACN as 
Chapter-1                                                                                                    Introduction 
 
Dept of Pharmaceutical Analysis           13             EGS Pillay College of Pharmacy 
 
 
 
mobile phase suggesting the use of non-aqueous reverse phase chromatography or 
normal phase HPLC. 
1.4.6 Method Development          
One approach is to use an isocratic mobile phase of some average organic solvent 
strength (50%). A better alternative is to use a very strong mobile phase first                          
(80-100%) then reduce %B as necessary. The initial separation with 100% B results in 
rapid elution of the entire sample, but few groups will separate. Decreasing the 
solvent strength shows the rapid separation of all components with a much longer run 
time, with a broadening of latter bands and reduced retention sensitivity. Goals that 
are to be achieved in method development are briefly summarized in Table 5. 
Table: 5 
 
 
Goal  Comment 
Resolution Precise and rugged quantitative analysis requires that Rs be 
greater than 1.5. 
Separation time <5-10 min is desirable for routine procedures. 
Quantitation £2% for assays; £5% for less-demanding analyses 
 £15% for trace analyses. 
Pressure <150 bar is desirable, <200 bar is usually essential (new column 
assumed). 
Peak height Narrow peaks are desirable for large signal/noise ratios. 
Solvent 
consumption 
Minimum mobile-phase use per run is desirable. 
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Separation or resolution is a primary requirement in quantitative HPLC. The 
resolution (Rs) value should be maximum (Rs > 1.5) favors maximum precision. 
Resolution usually degrades during the life of the column and can vary from day to 
day with minor fluctuations in separation conditions. Therefore, values of Rs=2 or 
greater should be the goal during method development for sample mixtures. Such 
resolution will favor both improved assay precision and greater method ruggedness. 
Some HPLC assays  do  not  require  base  line  separation  of  the  compounds  of  
interest (qualitative analysis). In such cases only enough separation of individual 
components is required to provide characteristic retention times for peak 
identification. 
 The time required for a separation (runtime = retention time for base band) 
should be as short as possible and the total time spent on method development is 
reasonable (runtimes 5 to 10 minutes are desirable). 
 Conditions for the final HPLC method should be selected so that the operating 
pressure with a new column does not exceed 170 bar (2500 psi) and an upper pressure 
limit below 2000 psi is desirable. There are two reasons for this pressure limit, despite 
the fact that most HPLC equipment can be operated at much higher pressures. First, 
during the life of a column, the backpressure may rise by a factor of as much as 2 due 
to the gradual plugging of the column by particulate matter. Second, at lower 
pressures (<170 bars) pumps, sample valves and especially auto samplers operate 
much better, seals last longer, columns tend to plug less and system reliability is 
significantly improved. For these reasons, a target pressure of less than 50 % of the 
maximum capability of the pump is desirable. When dealing with more challenging 
Chapter-1                                                                                                    Introduction 
 
Dept of Pharmaceutical Analysis           15             EGS Pillay College of Pharmacy 
 
 
 
samples or if the goals of separation are particularly stringent, a large number of 
method development runs may be required to achieve acceptable separation. 
1.4.7 Repeatable Separation 
As the experimental runs described above are being carried out, it is important to 
confirm that each chromatogram can be repeated. When we change conditions 
(mobile phase, column, and temperature) between method development experiments, 
enough time must elapse for the column to come into equilibrium with the new 
mobile phase and temperature.   
Usually column equilibration is achieved after passage of 10 to 20 volumes of the new 
mobile phase through the column.  However, this should be confirmed by repeating 
the experiment under the same conditions. When constant retention times are 
observed in two such back-to-back repeat experiments (± 0.5% or better), it can be 
assumed that the column is equilibrated and the experiments are repeatable. 
1.4.8 Optimization of HPLC Method 
During the optimization stage, the initial sets of conditions that have evolved from the 
first stages of development are improved or maximized in terms of resolution and 
peak shape, plate counts, asymmetry, capacity factor, elution time, detection limits, 
limit of quantitation and overall ability to quantify the specific analyte of interest. 
Optimization of a method can follow either of two general approaches: 
v Manual 
v Computer driven 
The manual approach involves varying one experimental variable at a time, while 
holding all other constant and recording changes in response. The variables might 
include flow rate, mobile or stationary phase composition, temperature, detection 
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wavelength and PH. This approach to system is slow, time consuming and potentially 
expensive. However, it may provide a much better understanding of the principles and 
theory involved and of interactions of the variables. 
 In the second approach, computer driven automated method development, 
efficiency is optimized while experimental input is minimized. This approach reduce 
the time, energy and cost of all instrumental method development. 
The various parameters that include to be optimized during method development are 
A. Selection of mode of separation. 
B. Selection of stationary phase. 
C. Selection of mobile phase. 
D. Selection of detector. 
1.4.8.1 Selection Of Mode Of Separation  
In reverse phase mode, the mobile phase is comparatively more polar than the 
stationary phase. For the separation of polar or moderately polar compounds, the most 
preferred mode is reverse phase. The nature of the analyte is the primary factor in the 
selection of the mode of separation .A second factor is the nature of the matrix. 
1.4.8.2 Selection of stationary phase 
Selection of the column is the first and the most important step in method 
development. The appropriate choice of separation column indicates three different 
approaches. 
Ø Selection of separation  
Ø The particle size and nature of the column packing 
Ø The physical parameters of the column i.e. the length and the diameter 
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Some of the important parameters considered while selecting chromatographic 
columns are 
Ø Length and diameter of the column  
Ø Packing material  
Ø Shape of the particles 
Ø Size of the particles 
Ø % of Carbon loading  
Ø Pore volume 
Ø Surface area 
Ø Reproducibility and reliability  
Ø End capping  
In this case, the column selected had a particle size of 5µm and an internal diameter of 
4.6mm.The column is selected depending on the nature of the solute and the 
information about the analyte. Reversed phase mode of chromatography facilities a 
wide  range  of  columns  like  dimethyl  silane  (C2),  butysilane  (C4), octysilane(C8), 
octadecylsane (C18),base deactivated silane (C18), BDS phenyl, cyanoproply (CN), 
nitro, amino etc. Silica based columns with different cross linking’s in the increasing 
order of Polarity are as follows:  
 
<…………. Non-polar …………… moderately polar…………. Polar. ……> 
                      C18 < C8 < C6 < Phenyl < Amino < Cyano < Silica 
 
C18 was chosen for this study since it is most retentive one. The sample 
manipulation becomes easier with this type of column. Generally longer columns 
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provide better separation due to higher theoretical plate numbers. Columns with 5µm 
particle size give the best compromise of efficiency. 
 Peak shape is equally important in method development. Columns that provide 
symmetrical peaks are always preferred while peaks with poor asymmetry can result 
in, 
· Inaccurate plate number and resolution measurement  
· Imprecise quantitation 
· Degraded and undetected minor bands in the peaks tail  
· Poor retention reproducibility 
  A useful and practical measurement of peak shape is peak asymmetry factor 
and peak tailing factor. Peak asymmetry is measured at 10% of full peak height and 
peak tailing factor at 5%. Reproducibility of retention times and capacity factor is 
important for developing a rugged and repeatable method. 
 A column which gives separation of all the impurities and degradants from 
each other and from analyte peak and which is rugged for variation in mobile phase 
shall be selected. 
1.4.8.3 Selection Of Mobile Phase 
The primary objective in selection and optimization of mobile phase is to achieve 
optimum separation of all the individual impurities and degradants from each other 
and from analyte peak. 
  In liquid chromatography, the solute retention is governed by the solute 
distribution factor, which reflects the different interactions of the solute-stationary 
phase, solute-mobile phase, and mobile phase-stationary phase. For a given stationary 
phase, the nature and the composition of which has to be judiciously selected in order 
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to get appropriate and required solute retention. The mobile phase has to be adapted in 
terms of elution strength (solute retention) and solvent selectivity (solute separation). 
Solvent polarity is the key word in chromatographic separations since a polar mobile 
phase will give rise to low solute retention in normal phase and high solute retention 
in reverse phase LC. The selectivity will be particularly altered if the buffer pH is 
close  to  the  pKa  of  the  analytes.  The  following  are  the  parameters,  which  shall  be  
taken into consideration while selecting and optimizing the mobile phase. 
v Buffer 
v pH of the buffer 
v Mobile phase composition 
1.4.8.4 Buffers if any and its strength: 
Buffer  and  its  strength  play  an  important  role  in  deciding  the  peak  symmetries  and  
separations. Some of the most commonly employed buffers are 
· Phosphate buffers prepared using salts like KH2PO4,  K2HPO4, NaH2PO4, 
Na2HPO4. 
· Phosphoric acid buffers prepared using H3PO4. 
· Acetate buffers-Ammonium acetate, Sodium acetate etc. 
· Acetic acid buffers prepared using CH2COOH. 
The retention also depends on the molar strengths of the buffer-Molar strength is 
increasingly proportional to retention times. The strength of the buffer can be 
increased, if necessary to achieve the required separations. The solvent strength is a 
measure of its ability to pull analyte from the column. It is generally controlled by the 
concentration of the solvent with the highest strength. The useful pH range for 
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columns is 2 to 8, since siloxane linkages are cleaved below pH-2 while at pH values 
above eight, silica may dissolve. 
1.4.8.5 Mobile phase composition: 
Most chromatographic separations can be achieved by choosing the optimum mobile 
phase composition. This is due to the fact that fairly large amount of selectivity can be 
achieved by choosing the qualitative and quantitative composition of aqueous and 
organic portions. Most widely used solvents in reverse phase chromatography are 
Methanol and Acetonitrile. Experiments should be conducted with mobile phases 
having  buffers  with  different  pH  and  different  organic  phases  to  check  for  the  best  
separations of analyte peak. A mobile phase which gives separation of analyte peak 
and which is rugged for variation of both aqueous and organic phase by at least ± 
0.2% of the selected mobile phase composition should be used. 
1.4.8.6 Selection Of Detector 
The detector was chosen depending upon some characteristic property of the analyte 
like UV absorbance, florescence, conductance, oxidation, reduction etc. The 
characteristics that are to be fulfilled by a detector to be used in HPLC determination 
are, 
Ø High sensitivity facilitating trace analysis.  
Ø Negligible baseline noise to facilitate lower detection.  
Ø Large linear dynamic range. 
Ø Low dead volume. 
Ø Inexpensive to purchase and operate. 
Pharmaceutical ingredients do not absorb all UV light equally, so that selection of 
detection wavelength is important. An understanding of the UV light absorptive 
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properties of the organic impurities and the active pharmaceutical ingredient is very 
helpful. For the greatest sensitivity λmax should be used. Ultra violet wavelengths 
below 200nm should be avoided because detector noise increases in this region. 
Higher wavelengths give greater selectivity. 
1.4.8.7 Performance Calculations 
           Carrying out system suitability experiment does the performance calculations. 
System suitability experiments can be defined as tests to ensure that the method can 
generate results of acceptable accuracy and precision. The requirements for system 
suitability are usually developed after method development and validations have been 
completed. The criteria selected will be based on the actual performance of the 
method as determined during its validation. For example, if sample retention times 
form part of the system suitability criteria, their variation SD can be determined 
during validation. 
          System suitability  might  then  require  that  retention  times  fall  within  a  ±3  SD 
range during routine performance of the method. 
          The USP (2000) defines parameters that can be used to determine system 
suitability prior to analysis include plate number (n), tailing factor (T), resolution (RS) 
and relative standard deviation (RSD) of peak height or peak area for respective 
injections. 
         The RSD of peak height or area of five injections of a standard solution is 
normally accepted as one of the standard criteria. For assay method of a major 
component, the RSD should typically be less than 1% for these five respective 
injections. 
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           The plate number and/ or tailing factor are used if the run contains only one 
peak. For chromatographic separations with more than one peak, such as an internal 
standard assay or an impurity method expected to contain many peaks, some measure 
of  separations  such  as  RS is recommended. Reproducibility of tR or k value for a 
specific compound also defines system performance. 
           The column performance can be defined in terms of column plate number. As 
the plate count is more the column is more efficient. 
1.4.9 METHOD VALIDATION 
The word “Validation” means “Assessment” of validity or action of proving 
effectiveness. 
1.4.9.1 Definition 
ICH defines validation as “establish the documented evidence which provides a high 
degree of assurance that a specific process will consistently produce a product of 
predetermined specifications and quantity attributes”. 
Method  validation  is  the  process  to  confirm  that  the  analytical  procedure  
employed for a specific test is suitable for its intended use. Methods need to be 
validated or revalidated. 
· Before their introduction into routine use 
· Whenever the conditions change for which the method has been validated, e.g., 
instrument with different characteristics 
· Whenever the method is changed, and the change is outside the original scope of 
the method. 
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1.4.9.2 Purpose Of Validation 
· Enable the scientists to communicate scientifically and effectively on technical 
matter. 
· Setting the standards of evaluation procedures for checking compliance and taking 
remedial action. 
· Economic: Reduction in cost associated with process sampling and testing. 
· As quality of the product cannot always be assured by routine quality control 
because of testing of statistically insignificant number of samples. 
· Retrospective validation is useful for trend comparison of results compliance to 
CGMP/CGLP. 
· Closure interaction with Pharmacopoeial forum to address analytical problems. 
· International Pharmacopoeial harmonization particularly in respect of impurities 
determination and their limits. 
Method validation is completed to ensure that an analytical methodology is accurate, 
specific, reproducible and rugged over the specified range that an analyte will be 
analyzed. Method validation provides an assurance of reliability during normal use, 
and is sometime referred to as "the process of providing documented evidence that the 
method does what it is intended to do."  
For method validation, these specifications are listed in USP Chapter <1225>, and can 
be referred to as the "Eight Steps of Method Validation," as shown in figure below. 
These terms are referred to as "analytical performance parameters", or sometimes 
as "analytical figures of merit."  
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The USP Eight Steps of Method Validation 
In response to this situation, one of the first harmonization projects taken up by the 
ICH was the development of a guideline on the "Validation of Analytical Methods: 
Definitions and Terminology." ICH divided the "validation characteristics" somewhat 
differently, as outlined in Figure below 
  
ICH Method Validation Parameters 
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1.4.9.3 Method Validation Parameters 
The developed methods were validated by following steps: 
A. Accuracy 
It is defined as closeness of agreement between the actual (true) value and mean 
analytical value obtained by applying a test method number of times. Spike and 
recovery studies are performed to measure accuracy: a known sample is added to the 
excipients and the actual drug value is compared to the value found by the assay. 
Accuracy is expressed as the bias or the % error between the observed value and the 
true value (assay value/actual value x 100%).  
The accuracy is acceptable if the difference between the true value and mean 
measured value does not exceed the RSD values obtained for repeatability of the 
method. 
The parameter provides information about the recovery of the drug from sample and 
effect of matrix, as recoveries are likely to be excessive as well as deficient.  
Procedure: 
Use a minimum of 3 spiking concentrations in the excipient solution. Prepare                        
two  samples  of  each  concentration.  Test  the  6  samples  in  triplicate  on  one  run.   
Measure expected vs. average measured value. Calculate the % recovery. 
B. Precision 
The precision of an analytical method is the degree of agreement among individual 
test results when the method is applied repeatedly to multiple sampling of 
homogenous sample. 
Precision is the measure of the degree of repeatability of an analytical method under 
normal operation and is normally expressed as the percent relative standard deviation 
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(%RSD)  or  coefficient  of  variation  (%  CV)  for  a  statistically  significant  number  of  
samples. According to the ICH, precision should be performed at three different 
levels: repeatability, intermediate precision, and reproducibility. 
Repeatability is the results of the method operating over a short time interval under 
the same conditions (or) is the % RSD of multiple determinations of a single sample 
in a single test run (intra-assay precision). It should be determined from a minimum of 
nine determinations covering the specified range of the procedure (for example, three 
levels,  three  repetitions  each)  or  from a  minimum of  six  determinations  at  100% of  
the test or target concentration. 
Procedure :  
§ Prepare three dilutions of the sample (high/medium/low concentrations in the 
range).  
§ Test 10 replicates of each dilution of the sample. 
§ Calculate the average and standard deviation for each point on the curve. 
§ Calculate the RSD for each point on the curve. 
Intermediate precision is the results from within lab variations due to random events 
such as different days, analysts, equipment, etc. In determining intermediate 
precision, experimental design should be employed so that the effects (if any) of the 
individual variables can be monitored (or) intermediate precision (also called inter-
assay precision) measures the % RSD for multiple determinations of a single sample, 
controls and reagents analyzed in several assay runs in the same laboratory.  
 Procedure:  
§ Prepare three dilutions of the sample (high/medium/low concentrations in the 
range). 
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§ Test triplicates of each dilution of the sample in three different assays. 
§ Do for day-to-day variations 
§ Do for lot-to-lot variations of assay materials 
§ Do for technician-to-technician variation. 
§ Calculate the average and standard deviation for each point on the curve for each 
individual test. 
§ Calculate the RSD for each point on the curve between the assay runs. 
Reproducibility refers to the precision between laboratories usually in collaborative 
studies and not directly relevant to assay validation in a manufacturing facility. 
Documentation in support of precision studies should include the standard deviation, 
relative standard deviation, coefficient of variation, and the confidence interval. 
C. Specificity 
It is the ability of an analytical method to assess unequivocally the analyte of interest 
in the presence of components that may be expected to be present, such as impurities, 
degradation products and matrix components. It is not possible to demonstrate that an 
analytical procedure is specific for a particular analyte. In such case a combination of 
two or more analytical procedure is recommended to achieve the necessary level of 
discrimination. Lack of specificity of an individual analytical procedure may be 
compensated by other supporting analytical procedures or tests. 
 In case of the assay, demonstration of specificity requires that the procedure is 
unaffected by the presence of impurities or excipients. In practice, this can be done by 
spiking the drug substances or product with appropriate levels of impurities or 
excipients and demonstrating that the assay is unaffected by the presence of these 
extraneous materials. If the degradation product impurity standards are unavailable, 
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specificity may be demonstrated by comparing the test results of samples containing 
impurities or degradation products to a second well-characterized procedure e.g., 
pharmacopoeia method or other validated analytical procedure (independent 
procedure). These comparisons should include samples stored under relevant stress 
conditions (e.g. light, heat humidity, acid/base hydrolysis, oxidation, etc.). 
D. Limit of Detection 
The limit of detection (LOD) is defined as the lowest concentration of an analyte in a 
sample that can be detected, not quantitated. It is a limit test that specifies whether or 
not an analyte is above or below a certain value. It is expressed as a concentration at a 
specified signal-to-noise ratio, usually two- or three-to-one. The ICH has recognized 
the signal-to-noise ratio convention, but also lists two other options to determine 
LOD: visual non-instrumental methods and a means of calculating the LOD. The 
method used to determine LOD should be documented and supported, and an 
appropriate number of samples should be analyzed at the limit to validate the level. 
Procedure  
· Prepare a standard concentration of the product in the appropriate solution. 
· Prepare a blank solution without any sample (zero concentration). 
· Perform the assay at least 3 times in duplicate according to the SOP. 
· Measure the amount present in the sample and blank. 
· Calculate the average for the sample and blank. 
· Calculate and standard deviation of the blank. 
· Calculate the LOD as 3.3 x SD /slope of linearity curve. 
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E. Limit of Quantitation 
The Limit of Quantitation (LOQ) is defined as the lowest concentration of an analyte 
in a sample that can be determined with acceptable precision and accuracy under the 
stated operational conditions of the method. That is, as the LOQ concentration level 
decreases, the precision increases. If better precision is required, a higher 
concentration must be reported for LOQ.  
Procedure: 
The calculation method is again based on the standard deviation of the response (SD) 
and the slope of the calibration curve (S) according to the formula: LOQ = 10(SD/S). 
Again, the standard deviation of the response can be determined based on the standard 
deviation of the blank, on the residual standard deviation of the regression line, or the 
standard deviation of y-intercepts of regression lines. 
F. Linearity : 
It is the ability of an assay to obtain test results, which are directly proportional to the 
concentration of an analyte in the sample. The determination of linearity will identify 
the range of the analytical assay. It can be measured as slope of the regression line 
and its variance or as the coefficient of determination (R2) and correlation                    
coefficient (R). 
Procedure: 
Determining the coefficient of correlation R for dilutions of the sample over the range 
claimed for the assay. 
1. Prepare 6 to 8 sample dilutions across the claimed range 
2. Test each dilution in triplicate for 3 runs 
3. Record expected values, actual values, and % recoveries for each run 
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4. Analyze each set of dilutions as a linear curve and calculate R for each assay. 
Alternative:  
Calculate the accuracy and precision at each dilution. Range is the highest                                                  
and lowest concentration with satisfactory accuracy and precision. 
If the validation study for an analytical test is well planned it should be possible to 
design the protocol to consider many of the parameters in a single series of tests, for 
instance: selectivity (specificity) linearity, range, accuracy and precision for a potency 
test. 
G. Range: 
Range is the interval between the upper and lower levels of analyte (inclusive) that 
have been demonstrated to be determined with precision, accuracy and linearity using 
the method as written.  If the relationship between response and concentration is not 
linear, the range may be estimated by means of a calibration curve. 
The range is normally expressed in the same units as the test results obtained by the 
method.  The  ICH  guidelines  specify  a  minimum  of  five  concentration  levels,  along  
with certain minimum specified ranges. For assay, the minimum specified range is 
from 80-120% of the target concentration. For an impurity test, the minimum range is 
from the reporting level of each impurity, to 120% of the specification. (For toxic or 
more potent impurities, the range should be commensurate with the controlled level).  
H. Ruggedness: 
Ruggedness, according to the USP, is the degree of reproducibility of the results 
obtained under a variety of conditions, expressed as %RSD. The ruggedness of an 
analytical  method  is  the  degree  of  reproducibility  of  test  results  obtained  by  the  
analysis  of  the  same  samples  under  a  variety  of  conditions  such  as  different  
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laboratories, different analysts, different instruments, different lots of reagents, 
different elapsed assay times, different assay temperatures, different days, etc. 
I. Robustness: 
ICH defines robustness as a measure of the method's capability to remain unaffected by 
small, but deliberate variations in method parameters. Robustness can be partly assured 
by good system suitability specifications. The evaluation of robustness should be 
considered during the development phase and depends on the type of procedure under 
study. It should show the reliability of an analysis with respect to deliberate variations 
in method parameters. If the results of a method or other measurements are susceptible 
to variations in method parameters, these parameters should be adequately controlled 
and a precautionary statement included in the method documentation. One consequence 
of the evaluation of robustness should be that a series of system suitability parameters 
(e.g., resolution test) is established to ensure that the validity of the analytical 
procedure is maintained whenever used. 
Examples of typical variations are: 
·  Stability of analytical solutions 
·  Extraction time 
In the case of liquid chromatography, examples of typical variations are 
· Influence of variations of pH in a mobile phase 
· Influence of variations in mobile phase composition 
· Different columns (different lots and/or suppliers) 
·  Temperature 
·  Flow rate. 
In the case of gas-chromatography, examples of typical variations are 
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· Different columns (different lots and/or suppliers) 
· Temperature 
· Flow rate. 
J. System Suitability Test (SST)  
SST  is  commonly  used  to  verify  resolution,  column  efficiency,  and  repeatability  of  
the chromatographic system to ensure its adequacy for a particular analysis. 
According to the United States pharmacopoeia (USP) and the International 
Conference  on  Harmonization  (ICH),  SST  is  an  integral  part  of  many  analytical  
procedure. 
Primary SST parameters are most important as they indicate system specificity, 
precision and column stability. Other parameter include capacity factor (K) and signal 
to noise ratio (S/N) for impurity peaks.  
The USP chromatography general chapter states (USP 36–NF 31, 621 – 
Chromatography) 
“System suitability tests are an integral part of gas and liquid chromatographic 
methods. They are used to verify that the resolution and reproducibility of the 
chromatographic system are adequate for the analysis to be done. The tests are based 
on the concept that the equipment, electronics, analytical operations and samples to be 
analyzed constitute an integral system can be evaluated as such.” 
1.5 Interpretation Of Chromatograms  
Figure below represents a typical chromatographic separation of two substances, 1 and 
2, where t1 and t2 are the respective retention times; and h, h/2, and Wh/2 are the height, 
the half-height, and the width at half-height, respectively, for peak 1. W1 and W2 are 
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the respective widths of peaks 1 and 2 at the  baseline. Air peaks are a feature of gas 
chromatograms and correspond to the solvent front in liquid chromatography.  
 
Figure  - 1 
Chromatographic retention times are characteristic of the compounds they represent 
but are not  unique. Coincidence of retention times of a test and a reference 
substance can be used as a feature in  construction of an identity profile but is 
insufficient on its own to establish identity. Absolute retention times of a given 
compound vary from one chromatogram to the next. 
1.5.1 Relative Retention times: 
Relative retention time is calculated by the equation Rr = t2/t1 
t2 = Retention time of test. 
t1 = Retention time of reference substance, determined under identical 
experimental conditions on the same column. 
1.5.2 Relative Retention: 
            t2- tM 
To calculate the relative retention (r) : -------------      
                                           t1- tM 
 
where tM is the retention time of the non-retained marker. 
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1.5.3 Resolution (as per USP) : 
The resolution, R, is a function of column efficiency, N, and is specified to ensure that 
closely eluting compounds are resolved from each other, to establish the general 
resolving power of the system, and  to ensure that internal standards are resolved 
from the drug.  
  
Figure - 2 
 
R is determined by the equation: 
 2(t2 - t1) 
R = 
 
 
 
W2 + W1 
 
 
    Or 
 
        2(t2 - t1) 
 R =  
 
 1.70 (W1, h/2 + W2, h/2) 
  
t2 and t1 are the retention times of the two components. 
W2 and  W1 are the corresponding width at the bases of the peaks obtained by 
extrapolating the relatively straight sides of the peaks to the base line. 
W1h/2 and W2 h/2 are the corresponding peak width at half-height. 
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1.5.4 Resolution (as per Ph.Eur) : 
 
 
     
Where,  tR2  >  tR1   
tR2 and   tR1 =  Retention  times  or  distances  along  the  baseline  from  the  point  of  
injection to the perpendiculars dropped from the maxima of two adjacent peaks  
Wh1 and Wh2 = peak width at half height  
1.5.5 Theoretical Plates (as per USP and Ph.Eur)  
Column efficiency also may be specified as system suitability requirements, especially 
if there is only one peak of interest in the chromatograms. The number of the 
theoretical plates, N, is a measure of column efficiency. It is calculated by the 
equation. 
 
 
t = Retention time of the substance. 
w  =  width  of  the  peak  at  its  base,  obtained  by  extrapolating  the  relatively  
straight sides of the peak to  the baseline. 
w½ = Peak width at half-height. 
1.5.6 Precision: 
Precision a measure of either degree of reproducibility or of repeatability is 
determined by making replicate injections of standard preparation and calculating 
relative standard deviation. Unless  otherwise specified in the individual monograph, 
data from five replicate injections of the standard  preparation are used to calculate 
 1.18(tR2 - tR1)  
 R =    
 (Wh1 + W h2) 
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the relative standard deviation (SR), if the requirement is 2.0% or  less; data from six 
replicate injections are used if the relative standard deviation requirement is more  than 
2.0%. 
Relative Standard Deviation in percentage. 
 
x = Arithmetic mean of the set. 
xi = An individual measurement in a set of N measurements. 
N  = Number of individual values  
1.5.7 Tailing Factor as per USP (or) Symmetry factor as per Ph.Eur: 
Tailing factor, T, a measure of peak symmetry, is unity for perfectly symmetrical 
peaks and its value  increases as tailing factor is pronounced (Fig 1). In some cases 
values less than unity may be observed. As peak asymmetry increases, integration and 
hence precision becomes less reliable. 
 
                               Figure - 3 
 
W0.05 = Width of peak at 5% height. 
f = Distance from the peak maximum to the leading edge of the peak, the distance is 
being measured at a point 5% of the peak height from baseline. 
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1.5.8 Capacity Factor (Mass distribution ratio): 
 Capacity factor k’ of a sample component is a measure of the degree which 
that component is retained by the column relative to an unretained component   
 Capacity factor is k’ = (tr - t0) / t0 
tr  - is the elution time of retained component and 
t0  - is the elution time of the unretained sample. 
1.5.9 Signal to Noise Ratio:   
     2H 
   S/N  = --------- 
      H 
Where,  
H  =   Height of the peak corresponding to the component concerned, in the 
chromatogram obtained with the prescribed reference solution, measured from the 
maximum  of  the  peak  to  the  extrapolated  baseline  of  the  signal  observed  over  a  
distance equal to 20 times the width at half-height  
 h  =   Range of the background noise in a chromatogram obtained after injection or 
application  of a blank, observed over a distance equal to 20 times the width at half- 
height of the peak in the chromatogram obtained with the prescribed reference solution 
and, if possible, situated equally around the place where this peak would be found.  
 
 
                                    Figure - 4 
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1.5.10 Peak to valley ratio  
The peak-to-valley ratio (p/v) may be employed as a system suitability requirement in  
a test for related substances when baseline separation between 2 peaks is not  reached  
   
Hp    =  Height above the extrapolated baseline of the minor peak,  
Hv = Height above the extrapolated baseline at the lowest point of the curve 
separating the minor and major peaks.  
 
 
Figure - 5 
      System Suitability Parameters and Recommendations: 
Parameter Recommendation 
Capacity Factor (k’) The peak should be well-resolved from other peaks and the void volume, generally k’>2.0 
Repeatability RSD </= 1% for N >/= 5 is desirable 
Relative retention  Not essential as long as the resolution is stated 
Resolution Rs of > 2 between the peak of interest and the closest eluting. 
Tailing Factor (T)  T of </= 2 
Theoretical 
Plates(N)    
In general should be > 2000 
 
Chapter-1                                                                                                    Introduction 
 
Dept of Pharmaceutical Analysis           39             EGS Pillay College of Pharmacy 
 
 
 
1.6 Statistical Parameters   
1.6.1 Linear regression: 
 Once a linear relationship has been shown to have a high probability by the 
value of the correlation coefficient ‘r’, then the best straight line through the data 
points has to be estimated. This can often be done be done by visual inspection of the 
calibration graph, but in many cases it is far more sensible to evaluate the best straight 
line by linear regression (the method of least squares). 
The equation of straight line is  
y = mx + c 
Where, y the dependent variable is plotted as result of changing x, the independent 
variable. 
 To obtain the regression line ‘y on x’ the slope ‘m’ of the line and the intercept 
‘c’ on the y axis are given by the following equation. 
m =   and   c =  
1.6.2 Correlation coefficient: 
When the changes in one variable are associated or followed by changes in the other, 
it is called correlation. To establish whether there is a linear relationship between two 
variables x1 and y1, use Pearson’s correlation coefficient r. 
                              r =                                         
Where n is the number of data points. 
The value of r must lie between +1 and -1, the nearer it is to +1, the greater the 
probability that a definite linear relationship exists between the variables x and y, 
values close to +1 indicate positive correlation and values close to -1 indicate negative 
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correlation values of ‘r’ that tend towards zero indicate that x and y are not linearly 
related (they made be related in a non-linear fashion). 
1.6.3 Standard deviation: 
The standard deviation measures the spread of the data about the mean value.         
It is commonly used in statistics as a measure of precision statistics as a measure of 
precision and is more meaningful than is the average deviation. It may be thought of 
as a root-mean-square deviation of values from their average and is expressed 
mathematically as 
( )
1N
xx
S
ni
1i
i
-
-
=
å
=
=  
Where, 
S is standard deviation. 
If N is large (50 or more) then of course it is immaterial whether the term in the 
denomination is N -1 or N  
Σ       = sum 
x       = observed values 
x       = Mean or arithmetic average= SX/N 
x -x  = deviation of a value from the mean 
N      = Number of observations 
1.6.4 Percentage relative standard deviation (%RSD): 
 It  is  also  known as  coefficient  of  variation  CV.  It  is  defined  as  the  standard  
deviation (S.D) expressed as the percentage of mean. 
                            C 100
x
S.DRSD  %or  V ´=  
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Where,   S.D   = standard deviation, 
  x       = Mean or arithmetic average. 
 The variance is defined as S2 and is more important in statistics than S itself.  
However, the latter is much more commonly used with chemical data. 
1.6.5 Standard Error of mean (S.E.): 
 Standard error of mean can be defined as the value obtained by division of 
standard deviation by square root of number of observations. It is mathematically 
expressed as                 
n
S.D.S.E. =  
 Where,   n = number of observations. 
            S.D = Standard deviation   
1.7 Data elements required for assay validation: 
It is not always necessary to evaluate every analytical performance parameter, as 
different  test  methods  require  different  validation  schemes.  The  Most  common  
categories of assays for which validation data should be required are as follows: 
                     i)  Quantitation of major components or active ingredients. 
                     ii)  Determination of impurities or degradation compounds. 
                     iii) Determination of performance characteristics 
Category-I: Analytical methods for quantitation of major components of bulk drug 
substances or active ingredients (including preservatives) in finished pharmaceutical 
products. 
Category-II: Analytical methods for determination of impurities in bulk drug 
substances or degradation compounds in finished pharmaceutical products. These 
methods includes quantitative assays and limit tests. 
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Category-III: Analytical methods for determination of performance characteristics 
(e.g. dissolution, drug release). 
            The type of method and its intended use dictates which parameters are required to be    
investigated. They are illustrated in the following Table 6. 
Table 6: Data elements required for assay validation 
Analytical 
Performance 
Parameter 
Assay 
Category-I 
Assay category-II Assay 
Category-
III Quantitative Limit Test 
 Accuracy Yes Yes * * 
 Precision Yes Yes No Yes 
 Specificity Yes Yes Yes * 
 LOD No No Yes * 
 LOQ No Yes No * 
 Linearity &    range Yes Yes No * 
 Ruggedness Yes Yes Yes * 
*may be required, depending on the nature of specific test. 
Table 7: Comparison of Analytical Parameters Required for Assay validation 
FDA reviewer Guidance USP General Chapter <1225> 
 ICH Q2A 
Guidelines 
Accuracy  Accuracy  Accuracy  
Precision Repeatability Analysis Precision  
Precision 
 
Intermediate  precision  No  Intermediate  precision  
Reproducibility  No  No  
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FDA reviewer Guidance USP General Chapter <1225> 
 ICH Q2A 
Guidelines 
Specificity /selectivity  Specificity  Specificity  
Detection limit  Detection limit  Detection limit  
Quantitation limit  Quantitation limit  Quantitation limit  
Linearity  Linearity  Linearity  
Range  Range  Range  
No  Ruggedness  No  
Robustness  Robustness  Robustness  
System suitability sample solution 
stability  System suitability  System suitability  
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2.0 LITERATURE REVIEW 
 
2.1 Suneetha and Raja Rajeswari, IJPSR, 2015; Vol. 6(5): 1915-1923., 
Estimation of Teriflunomide Along with Concomitant Drugs in Different 
Biological Matrices Using LC-MS/MS. Int J Pharm Sci Res 2015; 6(5): 
1915-23.doi: 10.13040/IJPSR.0975-8232.6(5).1915-23. 
The proposed validated method for the estimation of teriflunomide in different 
biological matrices is highly sensitive and rapid compared to published reports. 
The method offers significant advantages over those previously reported, in 
terms of lower sample requirements, simplicity of extraction procedure without 
any matrix effect. The efficiency of protein precipitation extraction and without 
any interference from the concomitant drugs make it an attractive procedure in 
bio analysis of teriflunomide.  
The linear dynamic range established was adequate to measure the 
concentration of teriflunomide in any preclinical and clinical study involving 
different biological species. The concomitant drugs also can be estimated along 
with the target analyte which is more advantageous than single compound 
analysis and also useful in drug interaction and toxicology studies. 
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2.2 Govind J. Kher, Vijay R. Ram, Kapil L. Dubal, Atul H. Bapodara and 
Hitendra. S. Joshi, Validation of a Stability-Indicating LC Method for 
Assay of Leflunomide in Tablets and for Determination of Content 
Uniformity. International Journal of ChemTech Research CODEN( USA): 
IJCRGG ISSN : 0974-4290, Vol. 3, No.2, pp 523-530, April-June 2011. 
In the present work, an analytical method based on LC using UV detection was 
developed and validated for assay and determination of content uniformity of 
leflunomide in tablet dosage forms. The analytical conditions were selected 
after  testing  the  different  parameters  that  effect  LC  analysis,  such  as  column,  
diluent, buffers, buffer concentration, organic solvent for mobile phase, 
proportion of mobile phase and concentration of analyte etc. The Wakosil 
column used because of its advantages of high retention, high resolving 
capacity, better reproducibility, low back pressure and low tailing. Our 
preliminary trials using different composition of mobile phases consisting of 
water with methanol or acetonitrile, did gave poor peak shape. By using 0.02M 
ammonium acetate buffer per 1000 mL and keeping mobile phase composition 
as of 0.02M ammonium acetate buffer and acetonitrile (40:60, v/v), best peak 
shape  was  obtained.  For  the  selection  of  organic  constituent  of  mobile  phase,  
acetonitrile was chosen to reduce the longer retention time and to attain good 
peak shape. A detection wavelength of 260 nm was selected after scanning the 
standard solution over the range 190-350 nm by using photo-diode array (PDA) 
detector. Detection at 260 nm resulted in good response and good linearity. 
The drug substance was easily extracted from the pharmaceutical dosage form 
by use of acetonitrile and buffer 50:50 (v/v). The tablet dispersed readily in 
buffer and the drug substance was freely soluble in acetonitrile. Solutions of 
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standard and test preparations were found to be stable in this solvent mixture. 
After developing the analytical method, it was validated. The analytical method 
validation gave evidence that the procedure was suitable for the intended 
purpose. The analytical method validation was carried out as per guidelines of 
ICH Q2 (R1), USP and AOAC INTERNATIONAL. 
 
2.3 Duygu Yeniceli, Dilek Dogrukol-Ak, , Muzaffer Tuncel. Department of 
Analytical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 
Eskisehir, Turkey. Determination of leflunomide in tablets by high 
performance liquid chromatography. Received 24 January 2005, Revised 
24 June 2005, Accepted 28 June 2005, Available online 19 August 2005 
In the present study, a reverse phase high performance liquid chromatography 
(HPLC) method was validated and applied for the determination of leflunomide 
in tablets. Chromatographic separation of leflunomide and oxazepam as an 
internal standard was carried out on a C18 column (50 mm, 3 mm i.d.) using a 
mobile  phase,  consisting  of  methanol  and  water  (60:40,  v/v),  at  a  flow rate  of  
0.5 ml min−1 and UV detection at 260 nm. The retention times for oxazepam 
and leflunomide were 2.6 and 5.2 min, respectively. The validated quantification 
range of the method was 2.7 × 10−6 to 5.5 × 10−5 M for leflunomide. The 
results of the developed procedure in tablets were compared with those of UV 
spectrophotometry to assess active leflunomide content. 
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2.4 Balraj Saini, Gulshan Bansal. Department of Pharmaceutical Sciences and 
Drug Research, Punjabi University, Patiala 147002, India. Isolation and 
characterization of a degradation product in leflunomide and a validated 
selective stability-indicating HPLC–UV method for their quantification. 
Received 14 May 2014, Revised 26 September 2014, Accepted 10 October 
2014, Available online 22 October 2014 
Leflunomide (LLM) is subjected to forced degradation under conditions of 
hydrolysis, oxidation, dry heat, and photolysis as recommended by International 
Conference on Harmonization guideline Q1A(R2). In total, four degradation 
products  (I–IV)  were  formed  under  different  conditions.  Products  I,  II  and  IV  
were formed in alkaline hydrolytic, acidic hydrolytic and alkaline photolytic 
conditions. LLM and all degradation products were optimally resolved by 
gradient elution over a C18 column. The major degradation product (IV) formed 
in hydrolytic alkaline conditions was isolated through column chromatography. 
Based on its 1H NMR, IR and mass spectral data, it was characterized as a 
British Pharmacopoeial impurity B. The HPLC method was found to be linear, 
accurate, precise, sensitive, specific, rugged and robust for quantification of 
LLM as well as product IV. Finally, the method was applied to stability testing 
of the commercially available LLM tablets. 
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2.5 D.S. Shokry, S.A. Weshahy Faculty of pharmaceutical sciences & 
pharmaceutical industries and M. Abdel Kawy Future University in Egypt. 
Faculty of Pharmacy, Cairo University. Application of Spectrophotometric 
and Chromatographic Methods for Stability Indicating Determination of 
Leflunomide. Journal of Applied Sciences Research, 8(3): 1547-1557, 2012 
ISSN 1819-544X 
Leflunomide, an amide containing compound, pyrimidine synthesis inhibitor a 
leading drug in treatment of moderate to severe rheumatoid arthritis.Four 
stability indicating methods are presented in this paper for the selective 
determination of Leflunomide in presence of its alkaline degradate. The 
resolution of the drug and its alkaline degradate has been achieved using 
derivative spectrophotometry including second-, third- and fourth derivatives. 
The derivative amplitudes are measured at 256.4 nm, 269.8 nm, 226.6 nm for 
D2, D3 and D4 respectively. The proposed methods were found to be linear 
over the range of (2.0-24.0 μgml-1). The fourth method is based on the 
chromatographic separation on a C18 column using a mobile phase of 0.01 M 
aqueous potassium dihydrogen phosphate adjusted at pH 3.5 with 
orthophosphoric acid, acetonitrile in a ratio of [30:70], a flow rate of 1 ml/min 
and UV detection at 262 nm. The proposed methods were validated with regard 
to accuracy, precision, selectivity, robustness, application to pharmaceutical 
preparation and further validated by applying standard addition technique. 
 
 
Chapter-3                                                                                   Aim and Objective 
Dept of Pharmaceutical Analysis           49             EGS Pillay College of Pharmacy 
 
3.0 AIM AND OBJECTIVE 
The drug analysis plays an important role in the development, manufacture and 
therapeutic use of drugs. Most of the pharmaceutical industries do the quantitative 
chemical analysis to ensure that the raw material used and the final product  thus 
obtained meet certain specification and to determine how much of each components 
are present in the final product. Standard analytical procedure for newer drugs or 
formulation may not be available in Pharmacopoeias; hence it is essential to develop 
newer analytical methods which are accurate, precise, specific, linear, simple and 
rapid. 
 
Aim: To develop and validate new RP HPLC method for the assay of Teriflunomide  
in tablet dosage. 
 
Objective:  Literature  survey  has  revealed  that  various  method  were  reported  for  
estimation of Teriflunomide. The existing methods are inadequate to meet the 
requirements; hence it is proposed to improve the existing methods and to develop 
new methods for the Estimation of Teriflunomide in pharmaceutical dosage forms. 
Hence, on the basis of literature survey it was thought to develop a precise, accurate, 
simple and reliable, less time consuming method for estimation.  
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4.0 PLAN OF WORK 
 
Plan of Work  
Ø Gather/ generate background information obtain physico-chemical properties.  
Ø Determine if special handling/treatment of sample is needed.  
Ø From physicochemical properties select detector parameters. 
Ø Calculate approximately separation parameters/isocratic or gradient mode. 
Ø Perform forced degradation experiments to challenge method. 
Ø Optimization separation conditions 
Ø Summarize methodology and finalize documentation. 
Ø Analysis of marketed formulations and Validate method. 
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5.0 DRUG   PROFILE 
Proper  Name : Teriflunomide 
Synonyms : Teriflunomide 
Structure   :  
 
 
Molecular formula : C12H9 F3 N2 O2 
IUPAC name : (Z)-2-Cyano-3-hydroxy-but-2-enoic acid-(4-trifluromethyl 
phenyl)-amide 
 (or)  
2-Cyano-3-hydroxy-N-[4-(trifluromethyl)phenyl]-2(Z)-
butenamide 
Molecular weight : 270.21 g/mol 
CAS No. : 163451818 
Melting point : 229 - 232°C 
Description : White to almost white powder 
Solubility : Sparingly soluble in acetone; slightly soluble in methylene 
chloride; very slightly soluble in acetonitrile; insoluble in 
water, ethanol and isopropyl alcohol.  
pH (1% in water) : 3.19 
Storage : Store at controlled room temperature, 15 to 30°C.               
Category : Teriflunomide is the active metabolite of leflunomide, and 
it acts as an immunomodulatory agent by inhibiting 
pyrimidine synthesis. 
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 Pharmacokinetic Data: 
Teriflunomide is the principal active metabolite of leflunomide and is responsible for 
leflunomide's activity in vivo. At recommended doses, teriflunomide and leflunomide 
result in a similar range of plasma concentrations of teriflunomide.  
Absorption : 
After oral administration of teriflunomide, maximum plasma concentrations are 
reached, on average, in 14 hours. 
Distribution: 
After a single intravenous dose, the volume of distribution is 11 L.  
Metabolism: 
Teriflunomide mainly undergoes hydrolysis to minor metabolites. Other minor 
metabolic pathways include oxidation, Nacetylation and sulfate conjugation. 
Teriflunomide is not metabolized by CYP450 or flavin monoamine oxidase. 
Elimination: 
Teriflunomide is eliminated unchanged and mainly through bile. Specifically 37.5% is 
eliminated in the feces and 22.6% in urine. 
Indications: 
Used in the treatment of relapsing forms of multiple sclerosis (MS). 
Pharmacology: 
Teriflunomide is an immunomodulatory agent that decreases the amount of activated 
CNS lymphocytes, which results in anti-inflammatory and antiproliferative effects. 
Mechanism of Action:    
The exact mechanism by which teriflunomide acts in MS is not known. What is 
known is that teriflunomide prevents pyrimidine synthesis by inhibiting the 
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itochondrial enzyme dihydroorotate dehydrogenase, and this may be involved in its 
immunomodulatory effect in MS. 
Adverse Effects: 
Most  common  adverse  reactions  (≥10%  and  ≥2%  greater  than  placebo):  ALT  
increased, alopecia, diarrhea, influenza, nausea, paresthesia and warning for 
Hepatotoxicity and risk of Teratogenicity 
Hepatotoxicity Severe liver injury including fatal liver failure has been reported in 
patients treated with leflunomide, which is indicated for rheumatoid arthritis.  
Risk of Teratogenicity Based on animal data, Teriflunomide may cause major birth 
defects if used during pregnancy.  
Toxicity:  
Teriflunomide is contraindicated in pregnant women or women of childbearing age 
due to the risk of teratogenicity. Teriflunomide is also contraindicated in severe 
hepatic impairment due to reports of  hepatotoxicity, hepatic failure, and death. 
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6.0 MATERIALS AND METHODS 
Table 8: Instrumentation 
S.NO Instrument Name Make Model 
1. HPLC Waters 2996 PDA 
2. Semi Micro Balance Sartorius CPA225D 
3. Micro Balance Sartorius CPA2P 
4. pH meter Thermo Electron Corporation Orion 3 Star 
5. Sonicator Spectra lab UCB70 
6. Centrifuge Apparatus Hermle centrifuge apparatus Not Available 
7. UV Visible Spectrophotometer Shimazdu UV-1700 
 
Table 9: Reagents and Chemicals 
S.No. Chemicals/Reagents Make/Grade 
1. Acetonitrile Merck, (HPLC-Grade) 
2. Potassium dihydrogen orthophosphate Merck (GR-Grade) 
3. Ortho phosphoric acid Merck (GR-Grade) 
4. Potassium Hydroxide Merck (GR-Grade) 
5. Ammonium acetate Merck (GR-Grade) 
6. Water Milli-Q Water 
 
Table: 10 Filters Used 
S.No. Name of the filter 
1. 0.45µm PVDF membrane filter (Manufactured by PALL) 
2. 0.45µm NYLON membrane filter (Manufactured by PALL) 
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Table: 11 Working/reference standards 
S.No Name of Working/reference standards 
1. Teriflunomide Working Standard (Manufactured by Glenmark) 
 
Table: 12 Test Sample 
S.No Name of Test Sample 
1. Teriflunomide Tablets, 14mg (Manufactured by Dr.Reddys) 
 
Table: 13 Column Used 
S.No Column Description 
1. X Bridge C8 column (150 x 4.6 mm, 5 µm particle size)              
2. Zorbax Eclipse  XDB C8 column (150 x 4.6 mm, 5 µm particle size)             
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METHOD DEVELOPMENT 
          The  objective  of  this  experiment  was  to  optimize  the  assay  method  for  
estimation of Teriflunomide tablets based on the literature survey  and the trails made. 
The trials mentioned bellow describes how the optimization was done. 
Trial 1: 
Buffer preparation : 50Mm of Ammonium Acetate buffer, filter through 
0.45µm  membrane filter and degas. 
Mobile Phase : Buffer and ACN (60:40). Sonicated to degas. 
Diluent : Water : ACN (30 : 70) 
Chromatographic conditions: 
Column   : X Bridge C8 column (150 x 4.6 mm, 5 µm particle 
size)   
Column temperature : 30°C 
Sample temperature : 5°C 
Elution mode : Isocratic 
Flow rate                    : 1.0 ml/min 
Injection volume      : 10ml 
Detector wave length : 294nm 
Run time                  : 10 min. 
Seal wash : 90:10 (Water: ACN) 
Needle wash : 10:90 (Water: ACN) 
System Suitability : USP Tailing Factor – NMT 2.0 and Plate count - NLT 
2000. 
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Conclusion  : The peak was observed but the Plate count is below 
2000. 
Trial 2:  
Buffer preparation : Similar to Trial 1 
Mobile Phase : Similar to Trial 1 
Diluent : Similar to Trial 1 
Chromatographic conditions: 
Column   : Zorbax Eclipse XDB C8 column (150 x 4.6 mm, 5 
µm particle size)   
Column temperature : 30°C 
Sample temperature : 5°C 
Elution mode : Isocratic 
Flow rate                    : 1.0 ml/min 
Injection volume      : 10ml 
Detector wave length : 294nm 
Run time                  : 10 min. 
Seal wash : 90:10 (Water: ACN) 
Needle wash : 10:90 (Water: ACN) 
System Suitability : USP Tailing Factor – NMT 2.0 and Plate count - NLT 
2000. 
Conclusion  : The peak was observed but the Plate count is below 
2000 and peak shape was asymmetrical.  
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Trial 3 (Optimized Method):       
Buffer preparation : 20Mm of Potassium dihydrogen orthophosphate 
buffer pH 2.40, filter through 0.45µm  membrane 
filter and degas. 
Mobile Phase : Buffer and ACN (65:35). Sonicated to degas. 
Diluent : Water : ACN (30 : 70) 
Chromatographic conditions: 
Column   : Zorbax Eclipse XDB C8 column (150 x 4.6 mm, 5 
µm particle size)   
Column temperature : 30°C 
Sample temperature : 5°C 
Elution mode : Isocratic 
Flow rate                    : 1.0 ml/min 
Injection volume      : 10ml 
Detector wave length : 250nm 
Run time                  : 10 min. 
Seal wash : 90:10 (Water: ACN) 
Needle wash : 10:90 (Water: ACN) 
System Suitability : USP Tailing Factor – NMT 2.0 and Plate count - NLT 
2000. 
Conclusion  : The peak was observed with good tailing and good 
shape, with plate count above 2000 (10721) and 
tailing factor below 2 (1.3). And this method was 
finalized for assay of Teriflunomide Tablets. 
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Preparation of Standard solution: 
Weigh accurately about 50 mg of Teriflunomide RS/WRS and transfer to a 200 mL 
volumetric  flask.  Add 140 mL of  diluent  and  sonicate  to  dissolve.  Dilute  to  volume 
with diluent and mix well.  
Transfer 10 mL of standard stock preparation into a 50 mL volumetric flask. Dilute to 
volume  with  diluent  and  mix  well.  (Concentration  of  about  50  µg/mL  of  
Teriflunomide). 
Preparation of Sample solution: 
Determine the Average weight using not less than 20 tablets. Weigh and finely 
powder not less than 20 tablets. Weigh accurately and transfer tablet powder 
equivalent to about 25 mg into a    100 mL volumetric flask. Add 70 mL of diluent 
and sonicate for 30 minutes with intermittent shaking. Dilute to volume with diluent 
and mix well. Centrifuge a portion of the above solution at 3500 rpm for 10 minutes. 
Transfer 5 mL of the supernatant solution to a 25 mL volumetric flask, dilute to 
volume with diluent and mix well.  
Filter a portion of the above solution through a 0.45 µm PVDF filter after discarding 
atleast the first 4 mL of the filtrate.  
(Sample preparation, concentration of about 50 µg/mL of Teriflunomide). 
 
Procedure: 
Equilibrate the column with mobile phase for not less than 30min at a flow rate of 1.0 
l/min. Separately inject 10 µl of Blank (diluent), Standard solution (five times) and 
Sample solution into the chromatographic system. Record the chromatograms and 
measure the peak responses. 
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System suitability: 
The column efficiency as determined for the Teriflunomide peak from standard 
solution is NLT 2000 theoretical plates. 
 Tailing factor for Teriflunomide peak obtained from standard chromatogram should 
be NMT 2.0 
 The % RSD for the Teriflunomide peak for 5 replicate injections of standard solution  
should be NMT 2.0 
The retention time of Teriflunomide peak is about 6.0 minutes. 
Calculations: 
Quantity of Teriflunomide Present in the tablet as % of labelled amount: 
                    AT            Ws        10         100          25            P           AW         
             =   -------- x--------- x ------- x -------- x -------- x -------- x ------ x 100 
                   AS           200         50          WT             5           100          L          
 
 
AT : Peak area of Teriflunomide from the chromatogram of the assay preparation 
AS : 
Mean peak area of Teriflunomide from the chromatogram of the standard 
preparation. 
Ws  : Weight of Teriflunomide working standard taken,  in mg 
WT : Weight of tablet powder taken,  in mg 
P : Potency of Teriflunomide working standard used in percent on as is basis 
L : Label claim in mg 
AV  : Average weight of tablet in mg 
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7.0 RESULTS AND DISCUSSION 
 
7.1 System Suitability: 
A Standard solution was prepared by using Teriflunomide working standards as per 
test method and was injected five times into the HPLC system. 
The system suitability parameters were evaluated from standard chromatograms. 
Acceptance criteria: 
1. The USP Tailing factor should be not more than 2.0 for Teriflunomide peak from 
standard solution. 
2. The USP Theoretical  plate  count  should  be  not  less  than  2000 for  Teriflunomide  
peak from standard solution. 
3. The RSD of Teriflunomide peak area is NMT 2.0% from five replicate injections 
of standard solution.  
    Table 14 System Suitability 
Injection Peak Area USP Plate count USP Tailing 
1 1616310 7147 1.27 
2 1617462 7192 1.28 
3 1621285 7096 1.28 
4 1618228 7215 1.27 
5 1610144 7220 1.28 
SD 1616686 --- --- 
% RSD 0.25 --- --- 
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Observation: 
The %RSD for peak areas, USP plate count and USP tailing were found to be within 
the limits.  
 
7.2 Accuracy: (Recovery): 
A study of Accuracy was conducted.  Drug Assay was performed in triplicate as per 
test method by spiking the Teriflunomide drug substance to the placebo  equivalent to 
5%, 50%, 100% and 200% of the labeled amount  as per the test method. The average 
% recovery of Teriflunomide was calculated.  
Separately inject the blank, placebo, Teriflunomide in to the chromatograph. 
Acceptance criteria: 
The mean % recovery of, Teriflunomide the at each level should be not less than 
95.0% and not more than 105.0%. 
Table 15 Accuracy 
Sample 
No. 
Theoretical 
(%) 
Mean Peak 
area  
% 
Recovery 
Mean (%) 
Recovery  
% RSD 
1 5 79271 99.37 
99.63 0.45 2 5 79243 99.37 
3 5 79893 100.15 
1 50 784059 100.65 
100.44 0.21 2 50 786797 100.22 
3 50 789985 100.46 
1 100 1589177 101.16 
101.05 0.28 2 100 1587887 100.73 
3 100 1593464 101.28 
1 200 3172132 101.92 
101.15 0.73 2 200 3155725 101.12 
3 200 3111902 100.43 
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Observation:     
 
The recovery results indicating that the test method has an acceptable level of 
accuracy. Therefore the method is accurate. 
 
 
7.3 Precision: 
A. System precision: Standard solution was  prepared as per test method and injected 
five times into chromatographic system. 
B. Method precision: Prepared six sample solutions as per test method and injected 
each solution into chromatographic system. 
Acceptance criteria: 
1. %RSD of %assay results from six samples should be NMT 2.0 
2. Assay should be in the range of test method i.e. not less than 95.0% and not more than 
105.0%. 
 
a) System Precision:  
Table 16 System Precision 
     
                                  
 
 
Concentration 
100% 
 
Injection Peak Areas Theoretical plates Tailing factor 
1 1616310 7147 1.27 
2 1617462 7192 1.28 
3 1621285 7096 1.28 
4 1618228 7215 1.27 
5 1610144 7220 1.28 
Statistical 
Analysis 
Mean 1616686 --- --- 
SD 1616686 --- --- 
% RSD 0.25 --- --- 
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    b) Method precision: 
  Table 17 Method Precision 
Sample No. Area %Assay 
1.  1570314 97.87 
2.  1574009 98.18 
3.  1594849 99.27 
4.  1590749 99.07 
5.  1606478 100.12 
6.  1609080 100.31 
Mean 99.13 
Standard Deviation 0.98848 
% RSD 0.99 
 
Observation:  
The precision study has shown that the test method is precise. 
 
7.4 Linearity of test method: 
Seven linearity solutions were prepared using Teriflunomide working standard at 
concentration levels from 5% to 150% of target concentration of Teriflunomide (5%, 
10%, 25%, 50%, 75%, 100% and 150%). The linearity graph plotted from 5% to 
150%.  
Acceptance criteria: 
             Correlation Coefficient should be not less than 0.999. 
             % of RSD for level 1 and Level 5 should be not more than 2.0. 
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     Table 18 Linearity 
Linearity Level Concentration (µg/mL) Average Area 
L1-5% 2.502 83096 
L2-10% 5.004 154525 
L3-25% 12.512 414647 
L4-50% 25.024 823580 
L5-75% 37.537 1241003 
L6-100% 50.049 1650624 
L7-150% 75.074 2510914 
 
  
 
 
Linear Regression Analysis  Concentration in µg/mL vs. Area 
Correlation Coefficient Square (r2) 0.9999 
Slope 33503.747 
Y-Intercept -8279.311 
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   Observation: 
The correlation coefficient was found to be 0.9999.  
From the above study it was established that the linearity of test method is from 5% to 
150% of the target concentration.  
 
Range: 
Data from linearity, precision, accuracy sections was considered to establish range of 
the method. The results were summarized in table 19. 
Acceptance Criteria:  
For linearity, correlation coefficient shall be ≥ 0.999.  
For precision, %RSD of assay of 6 replicate sample preparations shall be NMT 2.0%. 
For accuracy, individual recovery at each spike level should be within 95.0% to 
105.0% 
Table 19 Range 
Parameter Acceptance Criteria Result 
Linearity R ≥  0.999 0.999 
Precision %RSD of 6 Replicates NMT 2.0 0.99 
Accuracy Recovery 95.0% to 105.0% 99.99 
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7.5 Selectivity/Specificity: 
i) Placebo and impurity interference: 
A study to establish the interference of placebo was conducted. Blank, Standard, 
Placebo, Sample solution were prepared and injected into the chromatographic system 
for Identification and interference with the Teriflunomide peak. 
Acceptance Criteria: 
a. No interference should be observed from diluent, individual impurity and 
placebo at the retention time of Teriflunomide Peak.  
b. Teriflunomide Peak should be separated from the known and unknown 
impurities peak. (USP resolution NLT 1.5) 
Table 20 Placebo interference 
 
Observation: 
From the chromatograms, it was concluded that there was no interference with 
placebo as no peaks were observed at the retention times of Teriflunomide peaks. 
 
 
Sample Name Retention Time (minutes) Interference 
Blank Not Detected Nil 
Standard NA NA 
Placebo Not Detected NA 
Control Sample NA NA 
Spiked Sample NA NA 
Impurity A 2.597 Nil 
Impurity B 6.295 Nil 
Impurity C 19.041 Nil 
Impurity D 18.111 Nil 
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ii) Interference from degradation products: 
               A study was conducted to demonstrate the effective separation of degradants 
from Teriflunomide. Separate portions of Drug product and Placebo were exposed to 
following stress conditions to induce degradation. 
a) Acid  stress  
b) Base stress 
c) Peroxide stress 
d) UV light stress 
e) Heat stress 
f) A sample solution was prepared as per the method. 
 
Acid  Stress Sample: 
Weighed accurately and transferred Teriflunomide tablet powder equivalent to 25 mg 
of  Teriflunomide  into  a  100  mL volumetric  flask.   Added 35  mL of  RS-diluent  and  
sonicated for 30 minutes with intermittent shaking. 3mL of 1N HCL was added and 
heated on a water bath at 80°C for 3 hours. Cooled to room temperature and 
neutralized with 3 mL of 1N NaOH. Diluted to volume with RS-diluent and mixed 
well. Centrifuge a portion of the above solution at 3500 rpm for 10 minutes and 
further 5 mL of supernatant solution was transferred to 50 mL flask and diluted to 
volume with assay diluent and mixed well. Filtered through 0.45 µm PVDF filter by 
discarding the first 4 mL of the filtrate. 
Base Stress Sample: 
Weighed accurately and transferred Teriflunomide tablet powder equivalent to 25 mg 
of Teriflunomide into a 100 mL volumetric flask. Added 35 mL of RS-diluent and 
sonicated for 20 minutes with intermittent shaking. 3 mL of 1N NaOH was added and 
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heated on a water bath at 80°C for 8 hours. Cooled to room temperature and 
neutralized with 3 mL of 1 N HCl. Diluted to volume with RS-diluent and mixed 
well. Centrifuged a portion of the above solution at 3500 rpm for 10 minutes and 
further 5 mL of supernatant solution was transferred to 50 mL flask and diluted to 
volume with assay diluent and mixed well. Filtered through 0.45 µm PVDF filter by 
discarding the first 4 mL of the filtrate.  
Peroxide Stress Sample: 
Weighed accurately and transferred Teriflunomide tablet powder equivalent to 25 mg 
of Teriflunomide into a 100 mL volumetric flask. Added 20 mL of RS-diluent and 
sonicated for 30 minutes with intermittent shaking. 3 mL of 30% hydrogen peroxide 
was added and heated on a water bath at 80°C for 30 minutes. Cooled to room 
temperature, diluted to volume with RS-diluent and mixed well. Centrifuged a portion 
of the above solution at 3500 rpm for 10 minutes and further 5 mL of supernatant 
solution was transferred to 50 mL flask and diluted to volume with assay diluent and 
mixed well. Filtered through 0.45 µm PVDF filter by discarding the first 4 mL of the 
filtrate.  
UV Light Stress Sample:  
Weigh  accurately  and  transfer  tablet  powder  equivalent  to  about  25  mg(Stressed  
under UV light for 24 hours) into a 100 mL volumetric flask. Add 70 mL of diluent 
and sonicate for 30 minutes with intermittent shaking. Dilute to volume with diluent 
and mix well. Centrifuge a portion of the above solution at 3500 rpm for 10 minutes. 
Transfer 5 mL of the supernatant solution to a 25 mL volumetric flask, dilute to 
volume with diluent and mix well.  
Filter a portion of the above solution through a 0.45 µm PVDF filter after discarding 
atleast the first 4 mL of the filtrate.  
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Heat  Stress Sample:  
Weigh accurately and transfer tablet powder equivalent to about 25 mg(Heated at 
105°C for 1 hour and 30 minutes) into a 100 mL volumetric flask. Add 70 mL of 
diluent and sonicate for 30 minutes with intermittent shaking. Dilute to volume with 
diluent and mix well. Centrifuge a portion of the above solution at 3500 rpm for 10 
minutes. 
Transfer 5 mL of the supernatant solution to a 25 mL volumetric flask, dilute to 
volume with diluent and mix well.  
Filter a portion of the above solution through a 0.45 µm PVDF filter after discarding 
atleast the first 4 mL of the filtrate.  
 
Blanks were prepared in the similar way for Acid /Base reagent and for oxidation. 
Placebo Solutions were prepared in the similar way for control, Acid, Base, Peroxide, 
heat and UV light degradation. 
             
Acceptance Criteria: 
The net degradation should be in between 1% to 50%. 
All degradation Products should be separated from active. 
Purity angle should be less than purity Threshold.  
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Table 21 Forced Degradation Studies 
Sample 
Name Condition 
% 
Assay 
% 
Degradation 
Purity 
Angle 
Purity 
Threshold 
Control  
Sample 
NA 99.77 NA 0.034 0.201 
Spike 
Sample 
NA NA NA 0.036 0.213 
Acid  
Stress 
Sample 
3 mL 5N HCl, heated on a 
water bath at 80°C for 3 
hours. 
78.97 20.80 0.034 0.202 
Base 
Stress 
Sample 
3 mL 0.1N NaOH, heated 
on a water bath at 60°C for 
8 hours. 
99.65 0.12 0.034 0.201 
Peroxide 
Stress 
Sample 
3 mL 30% H2O2, heated 
on a water bath at 80°C for 
30 minutes. 
84.75 15.02 0.033 0.204 
UV light 
Stress 
Sample 
Stressed under UV light 
for 24 hours. 
100.77 NA 0.046 0.204 
Heat 
Stress 
Sample 
Heated in an oven at 
105°C for 
1 hour and 30 minutes. 
98.90 0.87 0.044 0.203 
 
Observation: 
During the Specificity and forced degradation, it was observed that no secondary peak 
arising from degraded samples interfered with the elution of the Teriflunomide Peak. 
Analysis of blank, individual impurities and placebo preparations demonstrated no 
interference with Teriflunomide Peak elution. Peak purity analysis using the 
photodiode array detector demonstrated Teriflunomide Peak homogeneity. Known 
and unknown impurities well separated from main peak (Resolution NLT 1.5).  The 
study validates that the method is specific and stability indicating.  
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7.6 Ruggedness of test method: 
System to system /Analyst to Analyst/column to Column variability:  
System to system /Analyst to Analyst/column to Column variability study was 
conducted on different HPLC systems, different columns and different analysts under 
similar conditions at different times. Six samples were prepared and each were 
analysed  as  per  test  method.  The  relative  standard  deviation  for  Teriflunomide  was  
found to be below 2 % on the columns, systems and Analysts.  
Comparison of both the results obtained on two different HPLC systems, different 
column and different analysts shows that the assay test method is rugged for System 
to system /Analyst to Analyst/column to Column variability. 
Acceptance criteria: 
1) The system suitability acceptance criteria as described in the method must be 
met. 
2) The % RSD of Teriflunomide from the six sample preparations should be not 
more than 2.0%. 
3) All assay values should be within the 90.0 – 110.0 % of label claim. 
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Table 22 System Suitability Ruggedness Results 
Injection No. 
Analyst-1 Analyst-2 
Peak area  Peak area  
1 1616310 1546066 
2 1617462 1556162 
3 1621285 1552999 
4 1618228 1555638 
5 1610144 1555822 
Mean 1616686 1553337 
% RSD 0.25 0.27 
Tailing factor 1.27 1.39 
Plate count 7147 7861 
 
Sample No 
Analyst-1 Analyst-2 
Mean Peak area % Assay Mean Peak area % Assay 
1 1570314 97.22 1533048 98.39 
2 1574009 97.51 1531820 98.43 
3 1594850 98.57 1543101 99.02 
4 1590749 98.36 1529833 98.21 
5 1606478 99.40 1536675 98.52 
6 1609080 99.62 1529051 97.82 
Mean NA 98.44 NA 98.40 
%RSD NA 0.98 NA 0.4 
Cumulative RSD of 12 samples assay value: 1.00 % 
 
Observation: The % of assay values obtained from six samples was between 90.0% 
and 110.0%. The RSD of assay from 6 samples is less than 2.0%.  
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7.7 Solution Stability 
Establish the stability of standard and sample solution on bench top for a period of 2 
days and in refrigerator for a period of about 5 to 7 days. Standard solution and 
sample solution were prepared as per test method injected and evaluated at initial, 
12Hr, 24Hr and 48Hr.   
The concentration of standard at 24 hours and 48 hours were compared to that of the 
initial. The assay of sample at 24 hours and 48 hours were compared to that of the 
initial.  
 
Acceptance Criteria:  
The concentration and % assay difference between the initial and time point for 
standard and sample solution should be NMT 2.0% from the initial value respectively. 
Table 23 Solution stability of standard at 5°C 
Time 
(hours) 
Mean Peak 
area 
Concentration 
(µg/mL) 
% Difference from 
Initial 
Initial 1616686 50.049 NA 
24 hours 1624042 50.709 -1.31 
48 hours 1633427 51.002 -1.90 
 
Table 24 Solution stability of sample at 5°C  
Time (hours) Mean Peak area Assay % 
% Difference from 
Initial 
Initial 1570315 97.22 NA 
24 hours 1582351 98.81 -1.63 
48 hours 1583676 98.89 -1.71 
 
Chapter-7                                                                                  Results and Discussion 
 
Dept of Pharmaceutical Analysis           75             EGS Pillay College of Pharmacy 
 
 
Observation: 
The concentration of the 24 and 48 hours injections of standard solution differed by 
less than 2.0% when compared to the initial standard solution and assay value of the 
24 hours and 48 hours of sample solution differed by less than 2.0% when compared 
to the initial sample solution. Therefore, the standard and sample solutions can be 
used up to 48 hours after its preparation if it is stored at 5°C.  
 
7.8 Filter Study: (At least two filters) 
For demonstrating that the filtration does not affect the analysis results. At least two 
types of filters were validated before use. 
A sample was prepared as per the method for the filter study. This sample was divided 
into three portions. One portion of the prepared sample was centrifuged at 3500 RPM 
for 10 minutes. The centrifuged sample was used as a control for the filter study. 
Second portion of sample was filtered through 0.45µ PVDF filter and the filtrate was 
collected  after  discarding  the  first  3  mL,  4  mL,  5  mL and  6  mL of  the  filtrate.  The  
third portion of sample was filtered through 0.45µ nylon filter and the filtrate was 
collected  after  discarding  the  first  3  mL,  4  mL,  5  mL and  6  mL of  the  filtrate.  The  
centrifuged and filtered samples were injected.  
Acceptance Criteria: 
Compare the results of the filtered samples with that of the centrifuged sample 
preparation. Difference between peak area response of centrifuged sample and filtered 
sample should be not more than 2.0%. 
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 Table 25 Filter study of 0.45µm PVDF and Nylon  filter 
Sample  Name 
Mean Peak 
area 
% Difference 
Centrifuged Sample (10 min @ 3500rpm) 1586029 NA 
0.45µ PVDF filtrate sample, 3 mL discarded 1580351 0.35 
0.45µ PVDF filtrate sample, 4 mL discarded 1582633 0.21 
0.45µ PVDF filtrate sample, 5 mL discarded 1589423 -0.21 
0.45µ PVDF filtrate sample, 6 mL discarded 1594893 -0.55 
0.45µ Nylon filtrate sample, 3 mL discarded 1608774 -1.43 
0.45µ Nylon filtrate sample, 4 mL discarded 1605951 -1.25 
0.45µ Nylon filtrate sample, 5 mL discarded 1613098 -1.70 
0.45µ Nylon filtrate sample, 6 mL discarded 1611165 -1.58 
 
Observation: 
The area found in the filtered fractions of sample solution was comparable to the area 
found in the centrifuged portion of the sample solution. There is no significant 
difference in area between different volumes 0.45µm PVDF and Nylon filtered. 
Therefore,  the  filters  are  suitable  for  use  and  the  discarding  of  4  mL  of  sample  
solution as filtrate, as stated in the method is a suitable volume to discard before 
collecting for analysis by HPLC.  
 
7.9 Robustness: 
The robustness is a measure of method capacity to remain unaffected by small, 
deliberate variations in method parameters and provides an indication of method 
reliability during normal use. 
 
A standard solution was prepared and injected into the chromatographic system as per 
the conditions specified in the method. The same standard solution was re-injected by 
changing one parameter at a time, keeping other parameters constant. A set of system 
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suitability data was calculated for standards injected under altered method conditions 
and compared against the values generated under normal method conditions.  
Method Parameters: 
1. Flow Rate (Normal flow is 1.5 mL/min) 
 
a. Flow minus → 1.35 mL/min 
b. Flow plus    → 1.65 mL/min 
 
2. Column Operating Temperature (Normal temperature is 30°C) 
 
a. Temperature minus → 25° C 
b. Temperature plus    → 35° C 
 
3. Buffer pH variation (Normal  Buffer pH 2.4) 
 
a. pH minus → pH 2.6 
b. pH plus   → pH 2.2 
  
4. Mobile Phase Composition Variation (Normal Composition is Buffer: ACN, 
650:350) 
 
a. MPV1  → Buffer : ACN (620:380) 
b. MPV2  → Buffer : ACN (580:420) 
 
Acceptance criteria: 
All the system suitability requirements must be met.  
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Table 26 Robustness study - Comparison of System 
Suitability and Retention time 
 
 
 
 
 
 
 
 
Parameters 
Retention 
Time 
(min)  
Mean 
Peak 
area 
(n=5)  
%RSD 
USP 
Tailing 
factor 
USP 
Plate 
count 
Normal Condition (1.0mL/min, 
30°C, 
pH 2.4 Buffer : ACN (650:350) 
6.564 1651509 0.61 1.25 7816 
Flow Rate Minus 
1.35 
mL/min 
7.292 1846396 0.23 1.26 8080 
Flow Rate Plus 
1.65 
mL/min 
5.996 1504834 0.35 1.24 7658 
Mobile phase         
pH Minus 
2.2 9.196 1585481 0.23 1.16 9241 
Mobile phase          
pH Plus 
2.6 5.683 1684507 0.21 1.33 6907 
Column 
Temperature 
Minus 
25°C 6.775 1677411 0.33 1.25 7756 
Column 
Temperature Plus 
35°C 6.144 1666426 0.09 1.25 8.35 
Mobile Phase 
composition 
Variation 1 
Buffer : 
ACN 
670:330 
9.215 1648619 0.17 1.23 8693 
Mobile Phase 
composition 
Variation 2 
Buffer:ACN 
630:370 
5.292 1665191 0.30 1.26 7259 
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Conclusion: 
No significant change was observed in retention time after individually changing the 
conditions of flow rate of mobile phase, column operating temperature and pH of 
buffer  and  mobile  phase  composition  variation.  Calculations  for  all  other  system  
suitability parameters met the acceptance criteria and the data generated are 
comparable with the normal conditions. Based on the above result, it is concluded that 
the method is unaffected by small, deliberate variations in flow rate, column 
temperature and pH of buffer and mobile phase composition variation. 
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CHROMATOGRAMS 
UV Spectrum 
 
Method Development trails in HPLC 
Trial No.1 
 
 
 
 
 
Chapter-7                                                                                  Results and Discussion 
 
Dept of Pharmaceutical Analysis           81             EGS Pillay College of Pharmacy 
 
 
Trial No. 2 
 
 
 
Trial No. 3 (Optimised method) 
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Diluent Effect: 
 
 
 
System Suitability 
 
Injection-1 
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Injection-2 
 
 
 
Injection-3 
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Injection-4 
 
 
 
Injection-5 
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Accuracy Chromatograms 
5% Sample 1 
 
 
 
5% Sample 2 
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5% Sample 3 
 
 
50% Sample 1 
 
 
 
 
 
 
Chapter-7                                                                                  Results and Discussion 
 
Dept of Pharmaceutical Analysis           87             EGS Pillay College of Pharmacy 
 
 
50% Sample 2 
 
 
50% Sample 3 
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100% Sample 1 
 
 
100% Sample 2 
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100% Sample 3 
 
 
 
200% Sample 1 
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200% Sample 2 
 
 
 
200% Sample 3 
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Method Precision Chromatograms 
 
Sample 1 - Injection-1 
 
 
 
Sample 1 - Injection-2 
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Sample 2 - Injection-1 
 
 
 
Sample 2 - Injection-2 
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Sample 3 - Injection-1 
 
 
 
Sample 3 - Injection-2 
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Sample 4 - Injection-1 
 
 
 
Sample 4 - Injection-2 
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Sample 5 - Injection-1 
 
 
 
Sample 5 - Injection-2 
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Sample 6 - Injection-1 
 
 
 
Sample 6 - Injection-2 
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Linearity Chromatograms 
L1 – 5% 
 
 
 
L1 – 10% 
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L1 – 25% 
 
 
 
L1 – 50% 
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L1 – 75% 
 
 
 
L1 – 100% 
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L1 – 150% 
 
 
 
Selectivity/Specificity Chromatograms 
 
Placebo and impurity interference: 
 
Placebo 
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Control Sample 
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Spiked Sample 
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Impurity A 
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Impurity B 
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Impurity C 
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Impurity D 
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Interference from degradation products: 
Acid  stress  
 
 
Chapter-7                                                                                  Results and Discussion 
 
Dept of Pharmaceutical Analysis           108             EGS Pillay College of Pharmacy 
 
 
Base stress 
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Peroxide stress 
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UV light stress 
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Heat stress 
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Solution Stability 
Standard – 24 Hrs 
 
Standard – 48 Hrs  
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Sample – 24 Hrs 
 
 
Sample – 48 Hrs  
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Filter Study 
Centrifuged Sample (10 min @ 3500rpm) 
Injection-1 
 
 
 
Injection-2 
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0.45µ PVDF filtrate sample, 3 mL discarded 
Injection-1 
 
 
 
Injection-2 
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0.45µ PVDF filtrate sample, 4 mL discarded 
Injection-1 
 
 
 
Injection-2 
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0.45µ PVDF filtrate sample, 5 mL discarded 
Injection-1 
 
 
 
Injection-2 
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0.45µ PVDF filtrate sample, 6 mL discarded 
Injection-1 
 
 
 
Injection-2 
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0.45µ Nylon filtrate sample, 3 mL discarded 
Injection-1 
 
 
 
Injection-2 
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0.45µ Nylon filtrate sample, 4 mL discarded 
Injection-1 
 
 
 
Injection-2 
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0.45µ Nylon filtrate sample, 5 mL discarded 
Injection-1 
 
 
 
Injection-2 
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0.45µ Nylon filtrate sample, 6 mL discarded 
Injection-1 
 
Injection-2 
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8.0 SUMMARY  
 A simple Reverse Phase High Performance Liquid Chromatographic method 
has been developed and subsequently validated for Teriflunomide tablets. 
The separation was carried out by using a Buffer : acetonitrile (65:35). The detection 
was carried out at 250nm. The column was Zorbax Eclipse XDB, C8,150 x 4.6mm, 
5µl. The flow rate was selected as 1.5ml/min.  
The Retention time of Teriflunomide tablets was found to be 6.0. The asymmetry 
factor or tailing factor of Teriflunomide tablets was found to be 1.2, which indicates 
symmetrical nature of the peak. The number of theoretical plates of Teriflunomide 
tablets was found to be 7391, which indicates the efficient performance of the 
column. These parameters represent the specificity of the method. 
From the linearity studies, specified concentration levels were determined. It was 
observed that Teriflunomide tablets were linear in the range of 5% to 150% for the 
target concentration by RP-HPLC. The linearity range of Teriflunomide tablets 5% to 
150% was found to obey linearity with a correlation coefficient of 0.999.  
The validation of the proposed method was verified by system precision and method 
precision by RP-HPLC. The %RSD of system suitability for Teriflunomide tablets 
was found to be 0.25.  
The validation of the proposed method was verified by recovery studies. The 
percentage recovery range was found to be satisfied which represent in results. The 
robustness studies were performed by changing the flow rate, filters and wavelength. 
The ruggedness study was also performed.  
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The analytical method validation was carried out by RP-HPLC as per ICH 
guidelines and given below are the tables are the summary of the results. 
 
Analytical method validation report for Teriflunomide tablets  
Table No. 27 
S. NO. TEST ACCEPTANCE CRITERIA RESULTS 
1. System 
Suitability 
 
 
The USP Tailing factor of 
Teriflunomide peak is NMT 2.0 
from standard preparation.  
 
 
The USP Plate count for 
Teriflunomide peak NLT 2000 from 
standard preparation. 
 
 
The  RSD  of  Teriflunomide  peak  
area  is  NMT  2.0%  from  five  
replicate injections of standard 
preparation. 
 
 
 
USP Tailing: 1.27 
 
 
 
 
USP plate count: 7147 
 
 
 
 
RSD: 0.25% 
 
2. Accuracy  The  recovery at each level must be 
97.0% to 103.0%.  
 
The RSD of all determinations at 
each level should be not more than 
2.0%. 
Average mean 
Recovery at 5% Level: 
99.63% 
RSD: 0.45 % 
 
Average mean 
Recovery at 50% 
Level: 100.44% 
RSD: 0.21 % 
 
Average mean 
Recovery at 100% 
Level: 101.05% 
RSD: 0.28 % 
 
Average mean 
Recovery at 200% 
Level: 101.15%  
RSD: 0.73 % 
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S. NO. TEST ACCEPTANCE CRITERIA RESULTS 
3. Method 
Precision 
 
All assay values should be within 
the 90.0–110.0 % of label claim. 
 
 
The  RSD  of  six  (6)  assay  values  
should be not more than 2.0%. 
 
Assay  
Mean:  99.13% 
 
 
RSD: 0.99% 
 
 
4. Linearity and 
range 
 
The correlation coefficient square 
(r2) must be NLT 0.997 
 
 
r2 = 0.9999 
 
5. Selectivity/ 
Specificity 
Any secondary peak arising from 
forced degradation study should not 
interfere with the Teriflunomide 
peak. 
 
 
The peak purity analysis using a 
photodiode array detector should 
demonstrate peak homogeneity. 
 
 
 
 
 
No interference should be observed 
from diluent, all known impurities 
at the retention time of 
Teriflunomide.  
 
 
 
Teriflunomide peak should be 
separated from the known and 
unknown impurities peak (USP 
resolution NLT 1.5). 
 
No interference 
observed. 
 
 
 
 
Demonstrated 
Teriflunomide peak 
homogeneity. 
No Interference 
observed. 
 
 
 
Teriflunomide  peak 
well separated from 
the known and 
unknown impurities 
peak  
 
 
USP resolution is 
more than 1.5 
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S. NO. TEST ACCEPTANCE CRITERIA RESULTS 
6. Ruggedness The system suitability acceptance 
criteria as described in the method 
must be met. 
 
 
 
 
 
 
 
 
The % RSD of Teriflunomide from 
the six sample preparations should 
be not more than 2.0%. 
 
 
 
All assay values should be within 
the 90.0 – 110.0 % of label claim. 
 
Analyst 1 
USP Tailing: 1.27 
USP plate count: 7147 
RSD: 0.25% 
 
Analyst 2 
USP Tailing: 1.39 
USP plate count: 7861 
RSD: 0.27% 
 
 
Analyst 1 
% RSD: 0.98% 
 
Analyst 2 
% RSD: 0.40% 
 
Analyst 1 
Assay  
Mean:  98.44% 
 
Analyst 2 
Assay  
Mean:  98.40% 
 
7. Solution 
stability 
The concentration  and  % assay 
difference between the initial and 
time point for standard and sample 
solution should be NMT 2.0% from 
the initial value respectively. 
Include an appropriate cautionary 
statement in the method based on 
the solution stability. 
Standard and samples  
solutions are stable up 
to 48 hours when 
stored at 5°C.  
8. Filter Study 
 
 
Compare the results of the filtered 
samples with that of the centrifuged 
sample preparation. Difference 
between peak area response of 
centrifuged sample and filtered 
sample should not be more than 
2.0%. 
 
Results of samples 
filtered by various 
filters (0.45µm PVDF 
and Nylon) are 
comparable with that 
of the centrifuged 
sample 
 
9. Robustness All the system suitability 
requirements must be met.  
Method is unaffected 
by deliberate 
variations in flow rate, 
column temperature, 
pH Variation and 
mobile phase 
composition. 
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9.0 CONCLUSION 
    
A HPLC method for Teriflunomide tablets was developed and validated in 
tablet  dosage  form  as  per  ICH  guide  lines.  The  results  of  this  validation  are  as  
summarized in the report. The results are found to be complying with the acceptance 
criteria for each of the parameter. 
 
Waters Alliance HPLC (Empower software with PDA detector) with Zorbax Eclipse 
XDB, C8,150 x 4.6mm, 5µ column, Injection volume of 10 µl is injected and eluted 
with the Mobile phase (Buffer and ACN, in the ratio of 65:35) which was pumped at a 
flow rate of 1.5 ml at 250 nm. The peak of Teriflunomide was found well separated at 
6.0 min. The developed method was validated for various parameters as per ICH 
guidelines like system suitability, accuracy, precision, linearity, specificity, 
ruggedness, robustness and solution stability. 
 
Hence it is concluded that the assay method is found to be valid in terms of 
reliability, precision, accuracy and specificity and hence it is suitable for routine 
analysis as well as for stability analysis. 
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